Payment overview · 2025
General Payments
$311.03
18 reported records · 9 companies
Healthcare provider profile · identity verified
Ralph D Hellams, MD
Allopathic & Osteopathic Physicians|Family Medicine · MANAKIN SABOT, VA · NPI 1053380352
Verified facts
What the public records show
CMS Open Payments records show Ralph D Hellams, MD received $311.03 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.80 | 21.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $59.66 | 19.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.88 | 12.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.72 | 10.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.42 | 9.8% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $28.37 | 9.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.79 | 7.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.49 | 5.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.90 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $311.03 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $59.66 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.51 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.51 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.72 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.72 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.42 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.42 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $28.37 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 347 | 83 |
| Furosemide | Furosemide | 284 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 277 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 40 |
| Potassium Chloride | Potassium Chloride | 169 | 28 |
| Eliquis | Apixaban | 163 | 22 |
| Metformin Hcl | Metformin Hcl | 134 | 35 |
| Mirtazapine | Mirtazapine | 129 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 27 |
| Trazodone Hcl | Trazodone Hcl | 111 | 23 |
| Lisinopril | Lisinopril | 102 | 23 |
| Carvedilol | Carvedilol | 97 | 20 |
| Omeprazole | Omeprazole | 95 | 21 |
| Buspirone Hcl | Buspirone Hcl | 91 | 17 |
| Sertraline Hcl | Sertraline Hcl | 86 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 19 |
| Donepezil Hcl | Donepezil Hcl | 73 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 20 |
| Alprazolam | Alprazolam | 71 | 14 |
| Montelukast Sodium | Montelukast Sodium | 68 | 11 |
| Levetiracetam | Levetiracetam | 65 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 15 |
| Xarelto | Rivaroxaban | 60 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 11 |
| Tramadol Hcl | Tramadol Hcl | 56 | 17 |
| Divalproex Sodium | Divalproex Sodium | 55 | suppressed |
| Gabapentin | Gabapentin | 51 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 12 |
| Famotidine | Famotidine | 47 | suppressed |
| Losartan Potassium | Losartan Potassium | 47 | 15 |
| Baclofen | Baclofen | 46 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 17 |
| Aripiprazole | Aripiprazole | 45 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 15 |
| Simvastatin | Simvastatin | 45 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Glipizide | Glipizide | 38 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 13 |
| Allopurinol | Allopurinol | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 30 |
| Metolazone | Metolazone | 37 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Prednisone | Prednisone | 32 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Lorazepam | Lorazepam | 30 | suppressed |
| Erythromycin Ethylsuccinate | Erythromycin Ethylsuccinate | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 27 | suppressed |
| Scopolamine | Scopolamine | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 15 |
| Gemtesa | Vibegron | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | 11 |
| Spironolactone | Spironolactone | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 14 |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $311.03 · 18 records | Novo Nordisk Inc | CAPLYTA, FARXIGA, INGREZZA, MOUNJARO, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error